Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.

Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.

The immunologists, honored with the 2018 award in Physiology or Medicine, pioneered immunotherapy, which harnesses the body’s immune system to fight cancer.

Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 

Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.

Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.